Tryptamine Therapeutics Statistics
Want to see AU:ENP full AI Analyst Report?
Tryptamine Therapeutics (ENP) Stock Statistics & Valuation Metrics
Total Valuation
Tryptamine Therapeutics has a market cap or net worth of AUD 47.39M. The enterprise value is AUD 48.24M.
- Market Cap
- AUD 47.39M
- Enterprise Value
- AUD 48.24M
Share Statistics
Tryptamine Therapeutics has 1,634,217,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,634,217,200
- Owned by Insiders
- 11.50%
- Owned by Institutions
- ―
Financial Efficiency
Tryptamine Therapeutics’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -66.04%.
- Return on Equity (ROE)
- -0.66
- Return on Assets (ROA)
- -0.58
- Return on Invested Capital (ROIC)
- -66.04%
- Return on Capital Employed (ROCE)
- -0.92
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.22M
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Tryptamine Therapeutics is -12.61. Tryptamine Therapeutics’s PEG ratio is -0.13.
- PE Ratio
- -12.61
- PS Ratio
- 0.00
- PB Ratio
- 6.62
- Price to FCF
- -13.89
- Price to Operating Cash Flow
- -14.32
- PEG Ratio
- -0.13
Income Statement
In the last 12 months, Tryptamine Therapeutics had revenue of 0 and earned -4.87M in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- -27.34K
- Operating Income
- -6.77M
- Pretax Income
- -6.78M
- Net Income
- -4.87M
- EBITDA
- -6.74M
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -3.41M and capital expenditures -5,571, giving a free cash flow of -3.41M billion.
- Operating Cash Flow
- -3.41M
- Free Cash Flow
- -3.41M
- Free Cash Flow per Share
- -0.00
Dividends & Yields
Tryptamine Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.20%
- Earnings Yield
- -9.98%
Stock Price Statistics
- Beta
- 0.43
- 52-Week Price Change
- -21.62%
- 50-Day Moving Average
- 0.04
- 200-Day Moving Average
- 0.03
- Relative Strength Index (RSI)
- 32.71
- Average Volume (3m)
- 1.40M
Important Dates
Tryptamine Therapeutics upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Feb 26, 2027
- Ex-Dividend Date
- ―
Financial Position
Tryptamine Therapeutics as a current ratio of 7.94, with Debt / Equity ratio of 0.00%
- Current Ratio
- 7.94
- Quick Ratio
- 7.94
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.83
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Tryptamine Therapeutics has paid -1.91M in taxes.
- Income Tax
- -1.91M
- Effective Tax Rate
- 0.28
Enterprise Valuation
Tryptamine Therapeutics EV to EBITDA ratio is -6.20, with an EV/FCF ratio of -12.26.
- EV to Sales
- 0.00
- EV to EBITDA
- -6.20
- EV to Free Cash Flow
- -12.26
- EV to Operating Cash Flow
- -12.28
Balance Sheet
Tryptamine Therapeutics has AUD 5.58M in cash and marketable securities with AUD 0.00 in debt, giving a net cash position of AUD 5.58M billion.
- Cash & Marketable Securities
- AUD 5.58M
- Total Debt
- AUD 0.00
- Net Cash
- AUD 5.58M
- Net Cash Per Share
- AUD 0.00
- Tangible Book Value Per Share
- AUD 0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Tryptamine Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 29.55%
Scores
- Smart Score
- 3
- AI Score
- 43
